Trofinetide (NNZ-2566) — ≥99% Research Peptide
Synthetic IGF-1 Tripeptide Analog — Approved for Rett Syndrome
A synthetic analog of the N-terminal tripeptide of IGF-1 (glycyl-L-prolyl-L-glutamate, GPE) — the first and only FDA-approved drug for Rett syndrome (DAYBUE®).
Research Applications & Benefits
- Synthetic IGF-1 N-terminal tripeptide analog
- FDA-approved for Rett syndrome (DAYBUE®, 2023)
- Orally bioavailable small molecule
- CNS-active neurotrophic research compound
Product Specifications
- Compound
- Trofinetide (NNZ-2566)
- CAS Number
- 853400-76-7
- Molecular Weight
- 341.4 g/mol
- HPLC Purity
- ≥99% (independently verified by CertikLabs)
- Category
- Cognitive
- Starting Price
- $129.00 USD
- Country of Origin
- United States
- Shipping
- Cold-chain insulated packaging, fast domestic delivery
- Payment
- Card, ACH, and cryptocurrency (10% discount)
Quality & Verification
Every Trofinetide (NNZ-2566) batch sold by PeptidesDirect is independently tested for purity (HPLC), identity (LC-MS), and concentration. A batch-specific Certificate of Analysis is available on request and anchored to a CertikLabs verification record for public inspection.
Frequently Asked Questions
Is Trofinetide (NNZ-2566) suitable for human consumption?
No. Trofinetide (NNZ-2566) is sold strictly for in-vitro laboratory research. It is not a drug, supplement, cosmetic, or food product and must not be administered to humans or animals.
What purity is Trofinetide (NNZ-2566)?
Trofinetide (NNZ-2566) ships at ≥99% verified by reverse-phase HPLC with mass-spec identity confirmation on every batch.
How is Trofinetide (NNZ-2566) shipped and stored?
Vials are shipped lyophilized in temperature-controlled packaging. Store unopened lyophilized peptide at −20°C; once reconstituted with bacteriostatic water, store at 2–8°C and use within 28 days.
Research Use Only. This product is intended for licensed laboratory research and is not for human or veterinary use.
